Sp1076

ADVANCES IN ENDOSCOPIC ERADICATION THERAPY - PUSHING THE BOUNDARIES

Date
May 21, 2024

Presenter

Speaker Image for Roos Pouw
Amsterdam UMC

Tracks

Related Products

Thumbnail for LOW RECURRENCE RATES AFTER ENDOSCOPIC RESECTION (R0) OF HIGH-RISK T1 ADENOCARCINOMA IN BARRETT’S ESOPHAGUS SUPPORT A STRICT ENDOSCOPIC SURVEILLANCE STRATEGY: PRELIMINARY RESULTS OF A PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT STUDY (PREFER)
LOW RECURRENCE RATES AFTER ENDOSCOPIC RESECTION (R0) OF HIGH-RISK T1 ADENOCARCINOMA IN BARRETT’S ESOPHAGUS SUPPORT A STRICT ENDOSCOPIC SURVEILLANCE STRATEGY: PRELIMINARY RESULTS OF A PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT STUDY (PREFER)
Optimal management following radical endoscopic resection (R0 ER) of T1 esophageal adenocarcinoma (EAC) is still a matter of debate due to conflicting reports on the risk for lymph node metastases (LNM). In case of histological risk factors for LNM, i.e…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
A variety of new developments in the realms of screening and surveillance of Barrett's esophagus have occurred in recent years. This session will focus on the current evidence base for risk assessment algorithms to enhance screening uptake, new screening tools and obstacles to implementation…
Thumbnail for STATE OF THE ART IN ENDOSCOIC ERADICATION THERAPY FOR BARRETT'S RELATED NEOPLASIA
STATE OF THE ART IN ENDOSCOIC ERADICATION THERAPY FOR BARRETT'S RELATED NEOPLASIA
Barrett's esophagus is the only precancerous condition for esophageal adenocarcinoma; a cancer that is associated with rising incidence and high morbidity and mortality rates…
Thumbnail for Maximizing Yield of Surveillance in Barrett's Esophagus
Maximizing Yield of Surveillance in Barrett's Esophagus
Understand the current limitations of current surveillance strategies in Barrett's esophagus